Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.

Article  PubMed  Google Scholar 

Montana M, Mathias F, Terme T, Vanelle P. Antitumoral activity of quinoxaline derivatives: a systematic review. Eur J Med Chem. 2019;163:136–47.

Article  CAS  PubMed  Google Scholar 

Zhang L, Xu Z. Coumarin-containing hybrids and their anticancer activities. Eur J Med Chem. 2019;181:111587.

Article  CAS  PubMed  Google Scholar 

Liang X-J, Chen C, Zhao Y, Wang PC. Circumventing tumor resistance to chemotherapy by nanotechnology. In: Zhou J, editor. Multi-drug resistance in cancer, Totowa, NJ: Humana Press; 2010, p. 467–88. https://doi.org/10.1007/978-1-60761-416-6_21.

Rashid ur H, Xu Y, Muhammad Y, Wang L, Jiang J. Research advances on anticancer activities of matrine and its derivatives: An updated overview. Eur J Med Chem. 2019;161:205–38.

Article  Google Scholar 

Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31–46.

Article  CAS  PubMed  Google Scholar 

Thiery JP, Acloque H, Huang RYJ, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139:871–90.

Article  CAS  PubMed  Google Scholar 

Ying H, Biroc SL, Li W, Alicke B, Xuan J-A, Pagila R, et al. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther. 2006;5:2158–64.

Article  CAS  PubMed  Google Scholar 

Green J, Cao J, Bandarage UK, Gao H, Court J, Marhefka C, et al. Design, synthesis, and structure–activity relationships of pyridine-based rho kinase (ROCK) inhibitors. J Med Chem. 2015;58:5028–37.

Article  CAS  PubMed  Google Scholar 

Boice A, Bouchier-Hayes L. Targeting apoptotic caspases in cancer. Biochim Biophys Acta Mol Cell Res. 2020;1867:118688.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Han Y, Dong W, Guo Q, Li X, Huang L. The importance of indole and azaindole scaffold in the development of antitumor agents. Eur J Med Chem. 2020;203:112506.

Article  CAS  PubMed  Google Scholar 

Liu M-M, Chen X-Y, Huang Y-Q, Feng P, Guo Y-L, Yang G, et al. Hybrids of phenylsulfonylfuroxan and coumarin as potent antitumor agents. J Med Chem. 2014;57:9343–56.

Article  CAS  PubMed  Google Scholar 

Wang L, Fang K, Cheng J, Li Y, Huang Y, Chen S, et al. Scaffold hopping of natural product evodiamine: discovery of a novel antitumor scaffold with excellent potency against colon cancer. J Med Chem. 2019;63:696–713.

Article  Google Scholar 

Cascioferro S, Parrino B, Carbone D, Schillaci D, Giovannetti E, Cirrincione G, et al. Thiazoles, their benzofused systems, and thiazolidinone derivatives: versatile and promising tools to combat antibiotic resistance. J Med Chem. 2020;63:7923–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kang D, Feng D, Sun Y, Fang Z, Wei F, De Clercq E, et al. Structure-based bioisosterism yields HIV-1 NNRTIs with improved drug-resistance profiles and favorable pharmacokinetic properties. J Med Chem. 2020;63:4837–48.

Article  CAS  PubMed  Google Scholar 

Ju Z, Su M, Hong J, La Kim E, Moon HR, Chung HY, et al. Design of balanced COX inhibitors based on anti-inflammatory and/or COX-2 inhibitory ascidian metabolites. Eur J Med Chem. 2019;180:86–98.

Article  CAS  PubMed  Google Scholar 

Gallardo-Godoy A, Gever J, Fife KL, Silber BM, Prusiner SB, Renslo AR. 2-Aminothiazoles as therapeutic leads for prion diseases. J Med Chem. 2011;54:1010–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Iino T, Tsukahara D, Kamata K, Sasaki K, Ohyama S, Hosaka H, et al. Discovery of potent and orally active 3-alkoxy-5-phenoxy-N-thiazolyl benzamides as novel allosteric glucokinase activators. Bioorg Med Chem. 2009;17:2733–43.

Article  CAS  PubMed  Google Scholar 

Khan I, Shareef MA, Kumar CG. An overview on the synthetic and medicinal perspectives of indenopyrazoles. Eur J Med Chem. 2019;178:1–12.

Article  CAS  PubMed  Google Scholar 

Wan Y, Long J, Gao H, Tang Z. 2-Aminothiazole: a privileged scaffold for the discovery of anti-cancer agents. Eur J Med Chem. 2021;210:112953.

Article  CAS  PubMed  Google Scholar 

Poupaert J, Carato P, Colacino E. 2(3H)-benzoxazolone and bioisosters as “privileged scaffold” in the design of pharmacological probes. Curr Med Chem. 2005;12:877–85.

Article  CAS  PubMed  Google Scholar 

Zheng S, Zhong Q, Jiang Q, Mottamal M, Zhang Q, Zhu N, et al. Discovery of a series of thiazole derivatives as novel inhibitors of metastatic cancer cell migration and invasion. ACS Med Chem Lett. 2013;4:191–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nayak PS, Narayana B, Sarojini BK, Hegde K, Shashidhara KS. Design and synthesis of novel heterocyclic acetamide derivatives for potential analgesic, anti-inflammatory, and antimicrobial activities. Med Chem Res. 2014;23:4280–94.

Article  CAS  Google Scholar 

Sun B, Dong Y, An Y, Liu M, Han J, Zhao L. et al. Design, synthesis and bioactivity evaluation of novel arylalkene-amide derivatives as dual-target antifungal inhibitors. Eur J Med Chem. 2020;205:112645.

Article  CAS  PubMed  Google Scholar 

Alizadeh SR, Hashemi SM. Development and therapeutic potential of 2-aminothiazole derivatives in anticancer drug discovery. Med Chem Res. 2021;30:771–806.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharma PC, Bansal KK, Sharma A, Sharma D, Deep A. Thiazole-containing compounds as therapeutic targets for cancer therapy. Eur J Med Chem. 2020;188:112016.

Article  CAS  PubMed  Google Scholar 

Klose W, Niedballa U, Schwarz K, Böttcher I. Nonsteroidal anti-inflammatory agents. 17. 4, 5-Bis-(4-methoxyphenyl)-2-arylthioazoles with antiphlogistic activity. Arch Pharm. 1983;316:941–51.

Article  CAS  Google Scholar 

Das D, Sikdar P, Bairagi M. Recent developments of 2-aminothiazoles in medicinal chemistry. Eur J Med Chem. 2016;109:89–98.

Article  CAS  PubMed  Google Scholar 

Chen R, Chen B. The role of dasatinib in the management of chronic myeloid leukemia. Drug Des Devel Ther. 2015;9:773–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pichot CS, Hartig SM, Xia L, Arvanitis C, Monisvais D, Lee FY, et al. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer. 2009;101:38–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang M, Yuang-Chi Chang A. Molecular mechanism of action and potential biomarkers of growth inhibition of synergistic combination of afatinib and dasatinib against gefitinib-resistant non-small cell lung cancer cells. Oncotarget. 2018;9:16533–46.

Article  PubMed  PubMed Central  Google Scholar 

Jin R-Y, Tang T, Zhou S, Long X, Guo H, Zhou J, et al. Design, synthesis, antitumor activity and theoretical calculation of novel PI3Ka inhibitors. Bioorganic Chem. 2020;98:103737.

Article